Expertise in
11
conditions

Jerome Cornillon

Saint ÉTienne
Saint-etienne-de-valoux, FR 
Expertise in
11
conditions
Saint ÉTienne
Saint-etienne-de-valoux, FR 

Overview

Jerome Cornillon practices practicing medicine in Saint-etienne-de-valoux, France.

Mr. Cornillon is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 119 peer reviewed articles and participating in 17 clinical trials.

Gender

Male

Locations

Saint Étienne
Saint-etienne-de-valoux, France
Other Locations
CHU De St Etienne, Caen, France
Saint-priest-la-vetre, France
Saint Étienne, France
108, Avenue Albert Raimond, Albert, 42000, France
Tours, France
Bordeaux, France
Rennes, France
CHU De ST Etienne, Saint-etienne, France
108 Bis, Avenue Albert Raimond, St Priest En Jarez, Sete, 42271, France
Boulogne-billancourt, 62321, France
Paris, France
Loire, France
Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Enrollment Status: Completed
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drugs: Obinutuzumab, Dexamethasone, Aracytine, Cisplatinum, Etoposide, Melphalan, Carmustine
Study Phase: Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC
Enrollment Status: Completed
Publish Date: August 02, 2024
Intervention Type: Other
Study Phase: Not Applicable
RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life: REACT Study
RElapse After Allograft: Link Between LoCus of Control and QualiTy of Life: REACT Study
Enrollment Status: Terminated
Publish Date: March 04, 2024
Intervention Type: Other
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (COSMOS)
Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (COSMOS)
Enrollment Status: Terminated
Publish Date: May 06, 2023
Intervention Type: Other
Study of Thromboelastography During Tranexamic Acid Treatment in Preventing Bleeding in Patients With Haematological Malignancies Presenting Severe Thrombocytopenia (TTRAP-bleeding)
Study of Thromboelastography During Tranexamic Acid Treatment in Preventing Bleeding in Patients With Haematological Malignancies Presenting Severe Thrombocytopenia (TTRAP-bleeding)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tranexamic acid
Study Phase: Phase 2
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Other
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients
Enrollment Status: Completed
Publish Date: January 31, 2023
Intervention Type: Biological
Study Phase: Phase 3
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drugs: Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Brentuximab
Study Phase: Phase 2
Validation of Radio-induced Damage Biomarkers : BIOM-DRI Study
Validation of Radio-induced Damage Biomarkers : BIOM-DRI Study
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Other
Study Phase: Not Applicable
SPPLAASH Study : a Randomized Study Aiming at Evaluating the Incidence of Post Lumbar Puncture Headache (PLPH) With the Use of Atraumatic Needles in Hematology
SPPLAASH Study : a Randomized Study Aiming at Evaluating the Incidence of Post Lumbar Puncture Headache (PLPH) With the Use of Atraumatic Needles in Hematology
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

119 Total Publications

Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)
Allogeneic haematopoietic stem cell transplantation in myelofibrosis: Patient selection, pre-transplant preparation and harmonisation of practices (SFGM-TC)
Journal: Bulletin du cancer
Published: January 28, 2026

Frequently Asked Questions about Jerome Cornillon

Is Jerome Cornillon a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Jerome Cornillon is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jerome Cornillon participate in research or clinical trials?

Yes. Jerome Cornillon has published 119 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Jerome Cornillon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cornillon's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile